- Home
- RERE vs PRAX Comparison
RERE vs PRAX Comparison
Compare RERE & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RERE
- PRAX
- Stock Information
- Founded
- RERE 2011
- PRAX 2015
- Country
- RERE China
- PRAX United States
- Employees
- RERE N/A
- PRAX N/A
- Industry
- RERE Other Specialty Stores
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- RERE Consumer Discretionary
- PRAX Health Care
- Exchange
- RERE Nasdaq
- PRAX Nasdaq
- Market Cap
- RERE 812.7M
- PRAX 950.8M
- IPO Year
- RERE 2021
- PRAX 2020
- Fundamental
- Price
- RERE $3.10
- PRAX $54.09
- Analyst Decision
- RERE
- PRAX Strong Buy
- Analyst Count
- RERE 0
- PRAX 10
- Target Price
- RERE N/A
- PRAX $101.00
- AVG Volume (30 Days)
- RERE 3.4M
- PRAX 475.8K
- Earning Date
- RERE 08-19-2025
- PRAX 08-04-2025
- Dividend Yield
- RERE N/A
- PRAX N/A
- EPS Growth
- RERE N/A
- PRAX N/A
- EPS
- RERE 0.07
- PRAX N/A
- Revenue
- RERE $2,388,301,386.00
- PRAX $8,122,000.00
- Revenue This Year
- RERE $27.37
- PRAX N/A
- Revenue Next Year
- RERE $24.06
- PRAX $3,567.38
- P/E Ratio
- RERE $43.06
- PRAX N/A
- Revenue Growth
- RERE 26.09
- PRAX 270.02
- 52 Week Low
- RERE $2.00
- PRAX $26.70
- 52 Week High
- RERE $4.35
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- RERE 42.55
- PRAX 56.75
- Support Level
- RERE $3.12
- PRAX $55.38
- Resistance Level
- RERE $3.67
- PRAX $59.27
- Average True Range (ATR)
- RERE 0.21
- PRAX 3.33
- MACD
- RERE -0.09
- PRAX -0.45
- Stochastic Oscillator
- RERE 4.00
- PRAX 27.37
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.